Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

The British Journal of Dermatology
P P M van LümigElke M G J de Jong

Abstract

Knowledge on the sequential treatment of psoriasis with biologics with regard to efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab in patients previously treated with etanercept. The relationship between the reasons for discontinuation of etanercept and the response to adalimumab is not clear in psoriasis. To evaluate the efficacy and safety of adalimumab in patients with psoriasis with primary failure, secondary failure or intolerance to etanercept in daily practice. Data were extracted from two prospective registries from all patients with psoriasis with failure on etanercept treatment, who switched to adalimumab therapy. Thirty patients fulfilled these criteria. All patients were naive to biologics when etanercept was initiated. Primary endpoints were the percentage of patients achieving a 50% or 75% improvement of the baseline Psoriasis Area and Severity Index (PASI) score (PASI 50 and PASI 75, respectively) at weeks 12, 24 and 48. Secondary endpoints were the percentage of patients achieving PASI 90, the mean percentage improvement in the PASI score from baseline and the adverse event rate. Compared with the baseline PASI score before the start of etanercept, the mean percentage impr...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Oct 4, 2005·Arthritis and Rheumatism·Philip J MeaseUNKNOWN Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
Sep 13, 2006·The British Journal of Dermatology·M de GrootJ D Bos
May 8, 2007·Journal of the American Academy of Dermatology·Kassie A Haitz, Robert E Kalb
Jun 19, 2007·Journal of the American Academy of Dermatology·Marina PapoutsakiSergio Chimenti
Jun 20, 2007·Annals of the Rheumatic Diseases·Ronald F van Vollenhoven
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Jan 31, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Gerard PitarchVicente Oliver
Apr 25, 2009·Arthritis Research & Therapy·Andrea Rubbert-Roth, Axel Finckh
May 15, 2009·Clinical and Experimental Dermatology·C RyanS Rogers
Jul 4, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·C L Martyn-SimmonsJ N W N Barker
Aug 8, 2009·American Journal of Clinical Dermatology·Annamaria MazzottaSergio Chimenti
Aug 12, 2009·The British Journal of Dermatology·L L A LecluseP I Spuls
Feb 17, 2010·Archives of Dermatology·Lidian L A LecluseGert-Jan Wolbink

❮ Previous
Next ❯

Citations

Jun 13, 2014·The Journal of Dermatological Treatment·Eduardo FonsecaLaida Elberdín
Oct 29, 2013·Expert Opinion on Biological Therapy·Bobbak MansouriAlan Menter
Aug 11, 2015·Dermatologic Therapy·Francisco Kerdel, Martin Zaiac
Aug 1, 2012·Journal of the American Academy of Dermatology·Paula P M van LümigElke M G J de Jong
Mar 6, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·R G Langley
Mar 16, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·P P M van LümigE M G J de Jong
Oct 25, 2012·The British Journal of Dermatology·J Leman, A D Burden
Dec 21, 2013·Journal of the American Academy of Dermatology·Stefano PiasericoUNKNOWN Psocare Study Group
May 3, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·L EissingM Augustin
Jun 18, 2014·Anais Brasileiros De Dermatologia·Laura Maria Andrade SilvaMaria de Fátima Santos Paim de Oliveira
May 11, 2017·The Journal of Dermatology·Hiromi HondaHidemi Nakagawa
Mar 17, 2015·Journal of Cutaneous Medicine and Surgery·Kathryn L Anderson, Steven R Feldman
Jun 25, 2017·The British Journal of Dermatology·L J van VugtE M G J de Jong
Nov 4, 2017·The Journal of Dermatological Treatment·G CarreteroUNKNOWN from the Spanish Group of Psoriasis
Sep 20, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·I VujicL Richter
Sep 22, 2010·The British Journal of Dermatology·Anthony D Ormerod
Jun 6, 2019·Anais Brasileiros De Dermatologia·Marcelo ArnoneTatiana Jerez Jaime
May 13, 2020·Expert Review of Clinical Pharmacology·Ya-Chu Tsai, Tsen-Fang Tsai
May 29, 2019·Immunotherapy·Ting-Shun Wang, Tsen-Fang Tsai

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.